@article{JTD7823,
author = {Ryan O. Parker and Adam B. King and Christopher G. Hughes},
title = {Dexmedetomidine for the treatment of hyperactive delirium refractory to haloperidol in non-intubated patients},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {7},
year = {2016},
keywords = {},
abstract = {Delirium is reported to occur in up to 89% of patients admitted to the intensive care unit (ICU) (1), and delirium is an independent risk factor for increased costs, longer hospital stays, neuropsychological dysfunction, and mortality (2-4). As such, the effective treatment of delirium represents a way to not only improve patient safety and outcomes but also to decrease costs and increase hospital throughput. Multiple modalities, including both typical and atypical anti-psychotics, are available as off-label use to treat the symptoms of delirium.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/7823}
}